医学
观察研究
重症监护医学
大流行
临床试验
神经氨酸酶
神经氨酸酶抑制剂
药品
疾病
2019年冠状病毒病(COVID-19)
免疫学
病毒
内科学
传染病(医学专业)
药理学
标识
DOI:10.1097/qco.0000000000000113
摘要
Clinicians, who may have only seen the media headlines following discussion of reviews which deal with randomized controlled trials of neuraminidase inhibitor drug use in mild uncomplicated influenza in the community, may be hesitant to prescribe these drugs. Observational data arising from treatment of severely ill individuals support use of these drugs early in illness and show improvement in outcomes associated with drug use.
科研通智能强力驱动
Strongly Powered by AbleSci AI